[go: up one dir, main page]

CL2015001900A1 - Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. - Google Patents

Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.

Info

Publication number
CL2015001900A1
CL2015001900A1 CL2015001900A CL2015001900A CL2015001900A1 CL 2015001900 A1 CL2015001900 A1 CL 2015001900A1 CL 2015001900 A CL2015001900 A CL 2015001900A CL 2015001900 A CL2015001900 A CL 2015001900A CL 2015001900 A1 CL2015001900 A1 CL 2015001900A1
Authority
CL
Chile
Prior art keywords
vaccines
higher density
carbohydrate antigen
saponin adjuvant
new
Prior art date
Application number
CL2015001900A
Other languages
English (en)
Inventor
Han Lee Wei
Wang Nan-Hsuan
Chang Chung-Hao
Hsieh Yih-Huang
Der Tony Yu Cheng
Wang Cheng-Chi
Lin Yu-Hsin
lin Yu-chen
Chen I-Ju
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of CL2015001900A1 publication Critical patent/CL2015001900A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA VACUNAS QUE COMPRENDEN ANTIGENO CARBOHIDRATO CONJUGADO A UNA TOXINA DIFTÉRICA (DT) COMO PROTEINA PORTADORA, EN LAS QUE LA PROPORCION DEL NUMERO DE MOLÉCULAS DE ANTIGENO CARBOHIDRATO CON RESPECTO AL DE MOLÉCULAS DE PROTEINA PORTADORA ES SUPERIOR A 5:1. EN EL PRESENTE DOCUMENTO, TAMBIÉN SE DESVELA UN NUEVO ADYUVANTE DE SAPONINA Y MÉTODOS DE INHIBICIÓN DE CÉLULAS CANCEROSAS MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE LA VACUNA DESVELADA EN EL PRESENTE DOCUMENTO.
CL2015001900A 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. CL2015001900A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361748880P 2013-01-04 2013-01-04

Publications (1)

Publication Number Publication Date
CL2015001900A1 true CL2015001900A1 (es) 2016-02-12

Family

ID=51062556

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015001900A CL2015001900A1 (es) 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
CL2015001902A CL2015001902A1 (es) 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina (divisional).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2015001902A CL2015001902A1 (es) 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina (divisional).

Country Status (17)

Country Link
US (2) US10517936B2 (es)
EP (2) EP2941436B1 (es)
JP (2) JP6359561B2 (es)
KR (2) KR102084301B1 (es)
CN (2) CN105026413B (es)
AU (2) AU2014203977B2 (es)
CA (2) CA2897084C (es)
CL (2) CL2015001900A1 (es)
ES (1) ES2843509T3 (es)
HK (1) HK1213266A1 (es)
IL (2) IL239785B (es)
PH (1) PH12015501519A1 (es)
RU (1) RU2015131033A (es)
SG (1) SG11201505301XA (es)
TW (2) TWI572356B (es)
WO (1) WO2014107652A2 (es)
ZA (1) ZA201504813B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510740YA (en) 2013-09-17 2016-01-28 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US9828436B2 (en) 2014-03-19 2017-11-28 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
JP6899321B2 (ja) * 2014-09-08 2021-07-07 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 糖脂質を使用するヒトｉＮＫＴ細胞活性化
ES2797747T3 (es) * 2014-09-15 2020-12-03 Obi Pharma Inc Composiciones de glucoconjugado inmunogénicas/terapéuticas y usos de las mismas
WO2016044164A1 (en) * 2014-09-15 2016-03-24 Wayne State University Novel synthetic anticancer, antifungal, and antibacterial vaccines
WO2017041027A1 (en) * 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3436482A4 (en) 2016-03-29 2020-03-11 OBI Pharma, Inc. ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
AU2017361549B2 (en) 2016-11-21 2023-12-21 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US20210396759A1 (en) * 2018-05-11 2021-12-23 Obi Pharma, Inc. Method for Predicting Human Immune Response
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN114805454B (zh) * 2021-01-21 2023-07-18 中国科学院生态环境研究中心 α-半乳糖神经酰胺类化合物及其制备方法和用途
CN114259559B (zh) * 2021-12-28 2024-03-19 天津科技大学 一种含有α-GalCer内源性佐剂的合成肿瘤疫苗
CN114306586A (zh) * 2022-01-04 2022-04-12 天津科技大学 基于tf抗原和壳寡糖内源性佐剂的肿瘤疫苗、方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
US6544952B1 (en) 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
IL122431A0 (en) * 1995-06-07 1998-06-15 Smithkline Beecham Biolog Combined vaccine comprising a polysaccharide antigen conjugated to a carrier protein
CN1215337A (zh) * 1995-06-23 1999-04-28 史密斯克莱·比奇曼生物公司 包含一种多糖抗原－载体蛋白共轭物和游离载体蛋白的疫苗
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
WO1998052573A1 (en) 1997-05-20 1998-11-26 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE10130545A1 (de) 2001-06-25 2003-01-09 Bosch Gmbh Robert Verfahren zum Betrieb einer Klimaanlage
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
JP5153990B2 (ja) * 2001-12-21 2013-02-27 シーエスエル、リミテッド 免疫反応性試薬およびサポニンを含有する組成物、およびその使用方法
US20060035267A1 (en) 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
CA2531023C (en) 2003-07-04 2013-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
CA2595906C (en) 2005-02-01 2014-04-22 Dyax Corp. Libraries and methods for isolating antibodies
WO2008128207A1 (en) 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
US8324742B2 (en) * 2008-04-01 2012-12-04 Texas Instruments Incorporated Alignment mark for opaque layer
CA2993582C (en) 2008-04-08 2020-12-15 Sloan-Kettering Institute For Cancer Research Triterpene saponins, methods of synthesis, and uses thereof
WO2010005735A2 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
US7928077B2 (en) 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
CN105535955B (zh) 2009-06-16 2019-04-23 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
WO2011156774A2 (en) 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
CA2867700A1 (en) 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
CA2897084C (en) * 2013-01-04 2019-07-16 Cheng Der Tony Yu Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104693305A (zh) 2013-12-04 2015-06-10 苏州中赢医疗科技有限公司 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
US11752204B2 (en) 2013-01-04 2023-09-12 Obi Pharma Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Also Published As

Publication number Publication date
AU2017200312B2 (en) 2018-05-17
IL239785B (en) 2018-05-31
TWI611810B (zh) 2018-01-21
IL258728A (en) 2018-06-28
JP6359561B2 (ja) 2018-07-18
ES2843509T3 (es) 2021-07-19
IL239785A0 (en) 2015-08-31
HK1213266A1 (zh) 2016-06-30
EP2941436B1 (en) 2020-12-02
AU2017200312A1 (en) 2017-02-02
JP2016504385A (ja) 2016-02-12
CA3044471C (en) 2021-05-11
US11752204B2 (en) 2023-09-12
AU2014203977A1 (en) 2015-07-09
CA2897084C (en) 2019-07-16
TWI572356B (zh) 2017-03-01
RU2015131033A (ru) 2017-02-09
IL258728B (en) 2019-07-31
SG11201505301XA (en) 2015-08-28
AU2014203977B2 (en) 2016-11-17
US20150328299A1 (en) 2015-11-19
CN105026413B (zh) 2020-04-24
KR20150111941A (ko) 2015-10-06
US20200061169A1 (en) 2020-02-27
US10517936B2 (en) 2019-12-31
TW201429488A (zh) 2014-08-01
PH12015501519A1 (en) 2016-04-18
CA2897084A1 (en) 2014-07-10
EP3792272A1 (en) 2021-03-17
JP6781204B2 (ja) 2020-11-04
KR101806370B1 (ko) 2017-12-07
ZA201504813B (en) 2017-11-29
CN111499679B (zh) 2021-07-06
KR102084301B1 (ko) 2020-03-03
KR20180053599A (ko) 2018-05-23
BR112015016381A2 (pt) 2017-07-11
WO2014107652A2 (en) 2014-07-10
EP2941436A4 (en) 2016-07-27
CN105026413A (zh) 2015-11-04
CL2015001902A1 (es) 2016-02-12
CA3044471A1 (en) 2014-07-10
EP2941436A2 (en) 2015-11-11
CN111499679A (zh) 2020-08-07
TW201718004A (zh) 2017-06-01
JP2018141021A (ja) 2018-09-13
WO2014107652A3 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
CL2015001900A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
CL2015002246A1 (es) Conjugados de anticuerpos drogas.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
SV2018005678A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2017000170A1 (es) Conjugados de fármacos con anticuerpos anti-cdh6
UY35399A (es) Conjugados de fármacos con anticuerpos
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
MX2016009807A (es) Polipéptidos que administran epítopos de cmh de clase i.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
JOP20190055A1 (ar) أجسام مضادة ضد cd27
AR101455A1 (es) Molécula portadora
MX2016002166A (es) Anticuerpos.
MX378368B (es) Receptores de antigeno y usos de los mismos.
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
MX372965B (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
AR096123A1 (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación